Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362115 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension
A Phase 2 study of Hypertension, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 449
- Enrollment target
- 20
- Study locations
NCT00362115: Completed Phase 2 study of Hypertension, sponsored by Takeda.
NCT00362115 is a Phase 2 study of Hypertension that has completed, run by Takeda. The registered enrollment target is 449 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00362115, a Phase 2 study of Hypertension, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 449 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
Primary Outcome
The change in sitting clinic diastolic blood pressure measured at final visit or week 8 relative to baseline. Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.
Conditions Studied
Interventions
- DRUG Azilsartan Medoxomil
Study Locations (20)
Florida
- - Hollywood
- - Jacksonville
- - Melbourne
- - Miami
- - Pembroke Pines
- - Pinellas Park
California
- - Carmichael
- - Long Beach
- - San Diego
- - Tustin
Connecticut
- - Stamford
- - Trumbull
- - Waterbury
Alabama
- - Huntsville
- - Ozark
Arizona
- - Mesa
Arkansas
- - Little Rock
Colorado
- - Denver
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 449 participants |
| Start Date | 2006-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
What the finished NCT00362115 record still lists
NCT00362115 is an interventional study that assigns participants to a tested intervention. The registered 449 participants enrollment target is mid-sized for trials with a published cap, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Azilsartan Medoxomil is the first listed.
NCT00362115 names 20 study sites across 9 states, led by Florida, California, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00362115 about?
NCT00362115 is a clinical study titled "Safety and Efficacy of Azilsartan Medoxomil in Participants With Mild to Moderate Hypertension". The purpose of this study is to evaluate the safety, efficacy, and tolerability of azilsartan medoxomil, once daily (QD), in individuals with hypertension.
What is the current status of trial NCT00362115?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 449 participants. The study started on 2006-05. Estimated completion is 2006-12.
What conditions does trial NCT00362115 study?
This clinical trial studies the following conditions: Hypertension.
What interventions are being tested in trial NCT00362115?
The interventions under investigation include: Azilsartan Medoxomil (DRUG).
Who is sponsoring clinical trial NCT00362115?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00362115 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00362115's enrollment target sits among peer trials
449 136th of 470 higher than 335 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
RECRUITING · Phase 2
-
A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients
RECRUITING · Phase 2
-
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
RECRUITING · Phase 2
-
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
RECRUITING · Phase 2
-
PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis
RECRUITING · Phase 2
-
Virtual Diabetes Group Visits Across Health Systems
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia